True Ventures, a venture capital firm focused on early-stage technology startups, led the investment. Other participants included Civilization Ventures and 415 Ventures, along with angel investors.
The 10-month-old company says it has invented a way to create human organs using 3-D printing. Initiatives to 3-D print organs are often hampered by an inability to create microvasculature, the small blood vessels that provide cells with oxygen and nutrients, according to the company.
The founders of Prellis Biologics, however, say they have discovered a way to build scaffolding that includes microvascular structures. They hope to bring their patent-pending technologies to the market in phases, first focusing on using lab-grown tissues to accelerate drug development and testing.
Eventually, they aim to distribute 3-D printed organs to patients to eliminate the wait for organ transplants.
“We believe our technology will jumpstart the practical use of lab-printed tissue for life-saving drug development, rapid development of human antibodies and production of human organs for transplant,” said Melanie Matheu, PhD, co-founder and CEO of Prellis Biologics.
More articles on health IT:
69% of IT security pros say threat intelligence is too complex for actionable insights: 5 survey insights
HIEs would lead to $3.1B annual reduction in US spending, study finds
Startup Insider: 5 questions with Edgility CEO Balaji Ramadoss on situational awareness
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
